Article

Dr. Adil Daud Discusses Zelboraf and Yervoy for the Treatment of Metastatic Melanoma

Dr. Adil Daud, Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF, discusses cost and the payer/provider relationship around metastatic melanoma medications.

vemurafenib (Brand name:

Dr. Daud discusses the use of Zelboraf) and ipilimumab (Brand name: Yervoy), the FDA-approved medications used in the treatment of metastatic melanoma. The medications are expensive, but Dr. Daud shares there have been little issue covering these specific drugs since they are so effective. Dr. Daud hopes that these are only the first class of this drug pathway extending life expectancy, as he hopes they can eventually bring metastatic melanoma to a chronic disease state and not a death sentence.

Related Videos
Shawn Griffin, MD, sitting for a video interview
Christine Funke, MD
John Michael O'Brien, PharmD, MPH
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
Dr Mingyang Song
Fran Gregory, PharmD, MBA, sitting for a video interview
Casey Koch, PharmD, sitting for a video interview
Dr K. Vish Viswanath
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo